{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Polyomavirus+Infections&page=2", "query": { "condition": "Polyomavirus Infections", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Polyomavirus+Infections&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T18:04:37.678Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01155258", "title": "Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer", "Hereditary Paraganglioma", "Male Breast Cancer", "Malignant Paraganglioma", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Pheochromocytoma", "Pancreatic Polypeptide Tumor", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Neuroendocrine Carcinoma of the Skin", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Pheochromocytoma", "Recurrent Prostate Cancer", "Recurrent Renal Cell Cancer", "Recurrent Small Cell Lung Cancer", "Recurrent Uterine Sarcoma", "Regional Gastrointestinal Carcinoid Tumor", "Regional Pheochromocytoma", "Stage III Cervical Cancer", "Stage III Endometrial Carcinoma", "Stage III Neuroendocrine Carcinoma of the Skin", "Stage III Ovarian Epithelial Cancer", "Stage III Ovarian Germ Cell Tumor", "Stage III Prostate Cancer", "Stage III Renal Cell Cancer", "Stage III Uterine Sarcoma", "Stage IIIA Breast Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Neuroendocrine Carcinoma of the Skin", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IV Uterine Sarcoma", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2010-06", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2016-06-13", "last_synced_at": "2026-09-25T18:04:37.678Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01155258" }, { "nct_id": "NCT06940440", "title": "IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Or Metastatic Merkel Cell Carcinoma" ], "interventions": [ { "name": "IFx-Hu2.0", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TuHURA Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2025-10", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-09-25T18:04:37.678Z", "location_count": 2, "location_summary": "Tampa, Florida • Madison, Wisconsin", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06940440" }, { "nct_id": "NCT03399981", "title": "Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Progressive Multifocal Leukoencephalopathy" ], "interventions": [ { "name": "Tysabri", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 80327, "start_date": "2017-06-01", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2024-03-19", "last_synced_at": "2026-09-25T18:04:37.678Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03399981" }, { "nct_id": "NCT01570283", "title": "ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Viral Infection" ], "interventions": [ { "name": "Multivirus-specific T cells Dose Level 1", "type": "BIOLOGICAL" }, { "name": "Multivirus-specific T cells Dose Level 2", "type": "BIOLOGICAL" }, { "name": "Multivirus-specific T cells Dose Level 3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AlloVir", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 21, "start_date": "2012-09", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2019-05-30", "last_synced_at": "2026-09-25T18:04:37.678Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01570283" }, { "nct_id": "NCT05859074", "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Squamous Cell Carcinoma", "SCC - Squamous Cell Carcinoma", "Basal Cell Carcinoma", "BCC", "BCC - Basal Cell Carcinoma", "Melanoma", "Merkel Cell Carcinoma", "Sebaceous Carcinoma", "Extramammary Paget Disease", "Kaposi Sarcoma", "Head and Neck Squamous Cell Carcinoma", "HNSCC", "Adnexal Carcinoma", "Angiosarcoma", "Cutaneous Neoplasm", "Advanced Cancer", "Metastatic Cancer", "Refractory Cancer", "Solid Tumor" ], "interventions": [ { "name": "MQ719", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2023-05-04", "completion_date": "2028-05-04", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-25T18:04:37.678Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05859074" }, { "nct_id": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Breast Cancer", "Merkel Cell Carcinoma", "Squamous Cell Cancer", "Non Small Cell Lung Cancer", "Cervical Cancer", "Urothelial Carcinoma", "Ovarian Cancer", "Hepatocellular Carcinoma", "Small-cell Lung Cancer", "Microsatellite Instability High", "Gastric Cancer", "Esophageal Cancer" ], "interventions": [ { "name": "Echopulse", "type": "DEVICE" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Standard of Care PD-1 Therapy", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-11-21", "completion_date": "2023-08-15", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-09-25T18:04:37.678Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04116320" }, { "nct_id": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "FT538", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Monoclonal antibody - Dose Escalation", "type": "COMBINATION_PRODUCT" }, { "name": "Monoclonal antibody - Dose Expansion", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-10-15", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-09-25T18:04:37.678Z", "location_count": 4, "location_summary": "Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05069935" }, { "nct_id": "NCT05013099", "title": "Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Merkel Cell Carcinoma, Unspecified", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "zirconium Zr 89 crefmirlimab berdoxam", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ImaginAb, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2021-12-09", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-07-22", "last_synced_at": "2026-09-25T18:04:37.678Z", "location_count": 6, "location_summary": "Little Rock, Arkansas • Duarte, California • Santa Monica, California + 3 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013099" }, { "nct_id": "NCT05422781", "title": "Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Merkel Cell Carcinoma" ], "interventions": [ { "name": "ITI-3000", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunomic Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-06-13", "completion_date": "2023-06-27", "has_results": false, "last_update_posted_date": "2023-11-22", "last_synced_at": "2026-09-25T18:04:37.678Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05422781" }, { "nct_id": "NCT07288073", "title": "TIL Therapy in cSCC and MCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Metastatic Cutaneous Squamous Cell Carcinoma", "Skin Cancer" ], "interventions": [ { "name": "LN-145", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Interleukin-2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Karam Khaddour, MD, MS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2026-02-10", "completion_date": "2029-06-29", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-09-25T18:04:37.678Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288073" } ] }